REPORT DESCRIPTION
Epinephrine Market – Dynamics
Increasing prevalence of food allergies is a major factor driving epinephrine market growth. According to a
research conducted by the Centers for Disease Control and Prevention (CDC) in 2013, in the U.S., from
1997 to 2011, food allergies among children increased around by 50%. Moreover, according to the
European Academy of Allergy and Clinical Immunology (EAACI), over 17 million people in Europe were
affected by food allergy in 2015. For instance, in November 2017, Kaléo, Inc. received the FDA approval
for its supplemental New Drug Application (sNDA) for AUVI-Q, the first and only epinephrine auto-
injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including
anaphylaxis, in infants and small children weighing 16.5 to 33 pounds.
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2401